CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETH

The Defense Logistics Agency awarded a delivery order to DMS PHARMACEUTICAL GROUP INC under solicitation SPE2D226F3063, issued on July 20, 2026, for the supply of one bottle of CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE, identified by NSN 6505015323362 and PR 7017560980, at a total price of $44.65. The item is to be delivered FOB destination to USNS EARL WARREN T-AO 207, FPO AP 96691-2900, with inspection and acceptance occurring at the delivery point, and the contractor responsible for all associated transportation and delivery costs. The award is issued under the parent contract SPE2DX25D9822, and the CAGE code 1UNB0 confirms the awardee’s identity, with additional manufacturer CAGE codes 0THL4 and 4QGW8 linked to National Drug Codes for traceability. The contract uses the NAICS code 424210 for pharmaceutical merchant wholesalers and is classified as a federal procurement under the Department of Defense, with no set-aside designation. Barcoded identifiers such as N210126200S193 and NSN are utilized for logistics tracking, and while compliance with DLA supply chain standards and DoD medical protocols is implied, no explicit MIL-STD or pharmaceutical specifications like USP are documented. No contract clauses, special requirements, or evaluation factors are explicitly stated in the available information, and there are no identified points of contact, accounting data, payment offices, or formal attachments. The delivery is firm, fixed-priced with zero variance tolerance and no option quantities, indicating a single, non-recurring transaction. The award notice was posted on DIBBS, and while the delivery logistics and product details are clearly defined, technical, compliance, and administrative details typically found in other contract sections remain unaddressed or are assumed through standard DLA procedures.